FIGO 2018 stage IB2 (>2 cm - ≤4 cm ) Cervical Cancer Treated with Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery (CoNteSSa) / Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NeoCon-F)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507230-24-00

Enrollment

Registered

2023-09-22

Start date

2021-02-17

Completion date

Unknown

Last updated

2025-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer

Brief summary

To determine the rate of functional uterus defined as successful fertility sparing treatment (completion of neo-adjuvant chemotherapy (NACT) followed by fertility sparing surgery (FSS) and no adjuvant therapy)

Interventions

DRUGCISPLATIN

DRUGPACLITAXEL

DRUGCARBOPLATIN

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
To determine the rate of functional uterus defined as successful fertility sparing treatment (completion of neo-adjuvant chemotherapy (NACT) followed by fertility sparing surgery (FSS) and no adjuvant therapy)	—

Countries

Italy, Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026